These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22192730)

  • 1. Biliary-tract cancer: improving therapy by adding molecularly targeted agents.
    Jensen LH
    Lancet Oncol; 2012 Feb; 13(2):118-9. PubMed ID: 22192730
    [No Abstract]   [Full Text] [Related]  

  • 2. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
    Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.
    Cassier PA; Thevenet C; Walter T; Baulieux J; Scoazec JY; Bancel B; Adham M; Souquet JC; Ponchon T; Lombard-Bohas C
    Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1111-7. PubMed ID: 20386107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
    Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
    Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
    Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.
    Gruenberger B; Schueller J; Heubrandtner U; Wrba F; Tamandl D; Kaczirek K; Roka R; Freimann-Pircher S; Gruenberger T
    Lancet Oncol; 2010 Dec; 11(12):1142-8. PubMed ID: 21071270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.
    Peraldo-Neia C; Cavalloni G; Fenocchio E; Cagnazzo C; Gammaitoni L; Cereda S; Nasti G; Satolli MA; Aprile G; Reni M; Avallone A; Spadi R; Venesio T; Martin V; Doglioni C; Frattini M; Aglietta M; Leone F
    PLoS One; 2018; 13(1):e0191593. PubMed ID: 29352306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
    Hezel AF; Noel MS; Allen JN; Abrams TA; Yurgelun M; Faris JE; Goyal L; Clark JW; Blaszkowsky LS; Murphy JE; Zheng H; Khorana AA; Connolly GC; Hyrien O; Baran A; Herr M; Ng K; Sheehan S; Harris DJ; Regan E; Borger DR; Iafrate AJ; Fuchs C; Ryan DP; Zhu AX
    Br J Cancer; 2014 Jul; 111(3):430-6. PubMed ID: 24960403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma.
    Thongprasert S; Napapan S; Charoentum C; Moonprakan S
    Ann Oncol; 2005 Feb; 16(2):279-81. PubMed ID: 15668284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
    Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
    Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
    Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
    Jang JS; Lim HY; Hwang IG; Song HS; Yoo N; Yoon S; Kim YH; Park E; Byun JH; Lee MA; Oh SJ; Lee KH; Kim BS; Oh SC; Kim SY; Lee SJ
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):641-7. PubMed ID: 19652971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Alberts SR; Al-Khatib H; Mahoney MR; Burgart L; Cera PJ; Flynn PJ; Finch TR; Levitt R; Windschitl HE; Knost JA; Tschetter LK
    Cancer; 2005 Jan; 103(1):111-8. PubMed ID: 15558814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive value of metabolic tumor volume on (18)F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib.
    Choi MK; Choi JY; Lee J; Heo JS; Choi SH; Choi DW; Lee KT; Lee JK; Lee KH; Park JO; Park YS; Lim HY
    Med Oncol; 2014 Jul; 31(7):23. PubMed ID: 24909509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer.
    Kim ST; Jang KT; Lee SJ; Jang HL; Lee J; Park SH; Park YS; Lim HY; Kang WK; Park JO
    BMC Cancer; 2015 Jul; 15():530. PubMed ID: 26189560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas.
    Kuhn R; Hribaschek A; Eichelmann K; Rudolph S; Fahlke J; Ridwelski K
    Invest New Drugs; 2002 Aug; 20(3):351-6. PubMed ID: 12201499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
    Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
    Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
    Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
    BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer.
    Lee KJ; Yi SW; Cha J; Seong J; Bang S; Song SY; Kim HM; Park SW
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):841-6. PubMed ID: 27586966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.